Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms by Čokić, Vladan et al.
Research Article
Proinflammatory Cytokine IL-6 and JAK-STAT Signaling
Pathway in Myeloproliferative Neoplasms
Vladan P. HokiT,1 Olivera MitroviT-AjtiT,1 Bojana B. Beleslin-HokiT,2
Dragana MarkoviT,1 Marijana BuaI,1 Miloš DikliT,1 Nada Kraguljac-KurtoviT,3
Svetozar DamjanoviT,2,4 Pavle MilenkoviT,1 Mirjana GotiT,3,4 and Puri K. Raj5
1 Institute for Medical Research, University of Belgrade, 11129 Belgrade, Serbia
2Clinic of Endocrinology, Diabetes and Diseases of Metabolism, Clinical Center of Serbia, 11000 Belgrade, Serbia
3Clinic of Hematology, Clinical Center of Serbia, 11000 Belgrade, Serbia
4Medical Faculty, University of Belgrade, 11000 Belgrade, Serbia
5Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration,
Silver Spring, MD 20993, USA
Correspondence should be addressed to Vladan P. Čokić; vl@imi.bg.ac.rs
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The recent JAK1/2 inhibitor trial in myeloproliferative neoplasms (MPNs) showed that reducing inflammation can be more
beneficial than targeting gene mutants. We evaluated the proinflammatory IL-6 cytokine and JAK-STAT signaling pathway related
genes in circulating CD34+ cells of MPNs. Regarding laboratory data, leukocytosis has been observed in polycythemia vera (PV)
and JAK2V617F mutation positive versus negative primary myelofibrosis (PMF) patients. Moreover, thrombocytosis was reduced
by JAK2V617F allele burden in essential thrombocythemia (ET) and PMF. 261 significantly changed genes have been detected
in PV, 82 in ET, and 94 genes in PMF. The following JAK-STAT signaling pathway related genes had augmented expression in
CD34+ cells of MPNs: CCND3 and IL23A regardless of JAK2V617F allele burden; CSF3R, IL6ST, and STAT1/2 in ET and PV
with JAK2V617F mutation; and AKT2, IFNGR2, PIM1, PTPN11, and STAT3 only in PV. STAT5A gene expression was generally
reduced in MPNs. IL-6 cytokine levels were increased in plasma, as well as IL-6 protein levels in bone marrow stroma of MPNs,
dependent on JAK2V617Fmutation presence in ET and PMF patients.Therefore, the JAK2V617Fmutant allele burden participated
in inflammation biomarkers induction and related signaling pathways activation in MPNs.
1. Introduction
It has been generally accepted that chronic inflammationmay
increase the risk of cancer by providing bioactive molecules
from the tumor microenvironment, including cytokines and
growth factors that promote continuous cell proliferation
and malignant transformation [1]. Interleukin-6 (IL-6) is a
member of the IL-6-type cytokines family with pro- and anti-
inflammatory properties. They activate the Janus tyrosine
kinase (JAK) family members (JAK1, JAK2, and TYK2),
leading to the activation of transcription factors of the signal
transducer and activator of transcription (STAT) family. All
IL-6-type cytokines potently activate STAT3 and to a minor
extent STAT1, while SOCS3 is the primary inhibitor of IL-
6 signaling [2, 3]. IL-6 is produced by a wide range of
cells including monocytes/macrophages, T cells, endothelial
cells, fibroblasts, and hepatocytes. IL-6 regulates a variety
of cell functions such as a cell proliferation, activation, and
differentiation and has been proposed as a predictor of
malignancy [4, 5].
IL-6 has been implicated as a critical activator of
myelopoiesis in response to chronic inflammatory disorders,
includingmyeloproliferative neoplasm (MPN) [6]. IL-6 levels
are increased in primarymyelofibrosis (PMF), with a positive
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correlation between IL-6 and angiogenesis in bone marrow
of MPN patients [7, 8]. The endogenous levels of IL-6 and
soluble IL-6 receptor are also elevated in essential thrombo-
cythemia (ET) [9]. It has been reported that although serum
level of IL-6 is not increased in polycythemia vera (PV),
the increased percentage of megakaryocytes secreting this
cytokine is observed in bonemarrow of patients with PV [10].
Activation of the JAK-STAT signaling pathway resulted in
the production of IL-6 [11]. Moreover, JAK2-specific inhibi-
tion blocks STAT3 phosphorylation and IL-6 production in
cancer cells [12]. STAT3 is predominantly activated by IL-6
receptor via JAK1/2 in cancer cell lines in association with
transcriptional silencing of SOCS-1 by hypermethylation [13].
Moreover, JAK1/2 inhibition decreases a circulating level of
proinflammatory cytokine IL-6 in MPN mouse model [14].
In a transgenic mouse model of Jak2V617F-mediated MPN,
JAK2 inhibitor normalizes the pathologically high plasma
concentrations of IL-6 [15]. Tumor necrosis factor-alpha
(TNF-𝛼) stimulated IL-6 production is also suppressed by
inhibition of JAK2 in multiple myeloma cells [16].
According to previous reports, proinflammatory cytokine
IL-6 demonstrates JAK-STAT signaling dependence and
has been augmented in MPNs. Majority of MPN patients
have JAK2V617Fmutation that constitutively stimulates JAK-
STAT pathway. Using microarray analysis, we explore both
JAK-STAT and IL-6 signaling related genes in MPNs accord-
ing to JAK2V617F mutant allele burden. IL-6 levels have
been examined both in peripheral blood and bonemarrow of
patients with MPN. In addition, genes related to other major
inflammatory pathways, such as transforming growth factor-
beta (TGF-𝛽) and nuclear factor-kappa B (NF-𝜅B), have been
evaluated in MPNs.
2. Material and Methods
2.1. Isolation of CD34+ Cells from the Peripheral Blood of
MPNPatients. Thestudywas approved by the Local Research
Ethics Committee (Medical School, University of Belgrade).
Informed consent was obtained from all patients included in
the study. All study de novo patients were subject to 30mL
of peripheral blood draw on one occasion, collected in 10%
sodium citrate. Each 30mL of diluted peripheral blood (1 : 1.2
with Ca2+/Mg2+-free phosphate buffer saline (PBS)) was lay-
ered gently on top of 15mL lymphocyte separation medium
(Capricorn Scientific GmbH, Ebsdorfergrund, Germany).
After centrifugation (400 g, 30min, 20∘C), the interface of
containing mononuclear cells was collected and washed
with PBS. The CD34+ cells were isolated from the collected
mononuclear cells by magnetic separation column (Super
Macs II, Miltenyi Biotec, Bergisch Gladbach, Germany) and
mixture of magnetic microbeads conjugated with antibody
against CD34 (Miltenyi Biotec) according to the manu-
facturer’s instructions. The viable CD34+ cell counts were
performed with the use of a trypan-blue exclusion technique
(BioWhittaker).Thehigh purity of recoveredCD34+ cells was
determined by flow cytometry using PE-anti-CD34mAb (BD
Biosciences, San Jose, CA, USA). Karyotype analysis did not
show any chromosome aberrations in samples formicroarray
analysis.
2.2. Isolation of Total RNA. We used the RNeasy protocol
for isolation of total RNA from CD34+ cells according to the
manufacturer’s instructions (Qiagen GmbH, Hilden, Germa-
ny). Concentration and integrity of total RNA were assessed
using NanoDrop spectrophotometer (Thermo Fisher Scien-
tific Inc., Wilmington, Delaware, USA) and Agilent 2100
Bioanalyzer Software (Agilent Technologies, Waldbronn,
Germany) comparing the ratio of 28S and 18S RNA peaks to
ensure that there is minimal degradation of the RNA sample.
2.3. DNA Sequencing. Genomic DNA was extracted from
peripheral blood granulocytes of MPN patients by using
the proteinase K and phenol-chloroform technique. Single
nucleotide mutation of JAK2V617F gene was characterized
by DNA sequencing after PCR amplification. PCR amplifi-
cation was performed with wild-type JAK-2-specific forward
primer 5󸀠-tggcagagagaattttctgaact-3󸀠 and reverse primer 5󸀠-
ttcattgctttcctttttcaca-3󸀠, confirmed by electrophoresis on an
ethidium bromide-impregnated 1% agarose gel. PCR ampli-
fied samples were analyzed by sequencing on an automated
ABI PRISM 3130 Genetic Analyzer (Applied Biosystems; Life
Technologies, Carlsbad, CA,USA)withABDNASequencing
Analysis Software (v5.2) by using the Big Dye Terminator v3.1
Ready Reaction Cycle Sequencing Kit.
2.4. Immunohistochemical Analysis. Bone marrow tissue sec-
tions were fixed in 10% neutral formalin solution for 24–36
hours and then decalcified in EDTA buffer for 3 hours and
embedded in paraffin. The tissue sections were cut at 5 𝜇m,
heated at 56∘C for 60min, and then deparaffinized and rehy-
drated through a series of xylenes and alcohols followed by




solution in PBS to block endogenous peroxidase activity. The
next step was incubation with anti-IL-6 antibody (Thermo
Scientific, dilution 1 : 400) in a humidity chamber overnight
at room temperature. Immunostaining was performed using
the streptavidin-biotin technique (LSAB+/HRP Kit, DAKO).
Immunoreactivity was visualized with DAKO Liquid DAB+
Substrate/Chromogen System counterstained with Mayer’s
hematoxylin (Merck, Whitehouse Station, NJ). For the neg-
ative control samples, normal serum and PBS buffer (1 : 500)
were pipetted without primary antibodies. Immunoreactive
cells were analyzed and scored at five powered fields in each
sample using a computer-supported imaging system (analysis
Pro 3.1) connected to the light microscope (Olympus AX70,
Hamburg, Germany) with an objective magnification of ×40.
Immunohistochemical staining for IL-6 was performed in
bone marrow of 34 subjects (10 PV: per 5 heterozygous and
homozygous; 9 ET: 5 no mutation and 4 heterozygous, and
9 PMF: 5 no mutation, 4 heterozygous for JAK2V617F, and 6
healthy subjects).
2.5. ELISA Assay. Peripheral blood samples were obtained
from 45 patients with newly diagnosed, untreated MPNs.
The study included 14 PV, 14 ET, and 17 PMF cases. Patients
were subclassified according to JAK2V617F mutational sta-
tus as JAK2 homozygous, JAK2 heterozygous, and patients
without mutation. We analyzed 7 PV homozygous and 7 PV
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heterozygous patients, 7 ET heterozygous and 7 ET patients
without JAK2V617F mutation, and 3 PMF homozygous, 7
PMF heterozygous, and 7 PMF patients without JAK2V617F
mutation.The control group comprised 7 healthy volunteers.
Blood samples were collected with EDTA, and plasma was
separated by centrifugation at 2000 rpm per 15 minutes. The
samples were stored at −80∘C until analysis. Plasma IL-6
level was measured using an ELISA kit (Thermo Scientific,
Rockford, IL, USA), according to the manufacturer’s instruc-
tions. All samples were tested in duplicate and data were
expressed as average of IL-6 levels in pg/mL for each group.
Measurements were performed on an ELISA Multiscan Plus
plate reader (Labsystems, Finland). Data were expressed as
mean± standard error of themean (SEM) of each group.They
were analyzed by Student’s t-test. A 𝑝 value < 0.05 was chosen
as the level of statistical significance.
2.6.MicroarrayAnalysis. Thehumanoligo probe set was pur-
chased fromOperonHumanGenomeArray-ReadyOligo Set
Version 4.0 (Eurofins MWG Operon, Huntsville, AL, USA)
which contains 35.035 oligonucleotide probes, representing
approximately 25.100 unique genes. We have followed the
MIAME (minimum information about a microarray exper-
iment) guidelines for the data presentation. Also, our prior
experience with primary cell cultures included quantitative
PCR with housekeeping genes (S16 and HPRT) to establish
similar efficiency of cDNA synthesis and PCR (data not
shown). In microarray studies, for determination of gene
expression in CD34+ cells of MPNs we used 8 healthy
donors and 9 ET (4 negative and 5 positive heterozygotes for
JAK2V617F mutation), 7 PV (3 heterozygotes and 4 homozy-
gotes for JAK2V617F), and 4 PMF (2 negative and 2 positive
for JAK2V617F) patients.We isolated a lowquantity of CD34+
cells that correspond to low mRNA levels insufficient for
microarray analysis, so we performed the amplification of
total RNA using the Amino Allyl MessageAmp II aRNA
Amplification kit (Life Technologies Corp., Carlsbad, CA,
US), according to manufacturer instruction. We used 0.3𝜇g
of total RNA from MPN patients for amplification. For
microarray analyses we used 3 𝜇g of amplified RNA. Total
human universal RNA (HuURNA), isolated from a collection
of adult human tissues to represent a broad range of expressed
genes from both male and female donors (BD Biosciences,
Palo Alto, CA), served as a universal reference control in
the competitive hybridization. All examined MPN sam-
ples were hybridized against HuURNA. For hybridization,
the hybridization mixture of cDNA probe and aRNA was
preheated at 100∘C for 2 minutes and centrifuged for 1
minute at 10.000 rpm. 20𝜇L of preheated (42∘C) Ambion
hybridization buffer (20x SSC in 10% SDS) was mixed with
hybridization mixture. Total volume of the hybridization
mixture was added on the array in slide and covered with
cover slip. Slideswere placed inMAUIhybridization chamber
(BioMicro Systems, Inc., Salt Lake City, UT, USA) and
incubated overnight at 42∘C. Slides were then washed for
4 minutes each in 1x SSC and 0.1x SSC and spin-dried.
Microarray slides were scanned in both Cy3 (532 nm) and
Cy5 (635 nm) channels using Axon GenePix 4000B scanner
(Axon Instruments, Inc., Foster City, CA) with a 10-micron
resolution. Scanned microarray images were exported as
TIFF files to GenePix Pro 3.0 software for image analysis.
The average of the total Cy3 and Cy5 signal gave a ratio that
was used to normalize the signals. Each microarray exper-
iment was globally normalized to make the median value
of the log
2
-ratio equal to zero. For advanced data analysis,
gpr and jpeg files were imported into microarray database
and normalized by software tools provided by NIH Center
for Information Technology (http://nciarray.nci.nih.gov/).
Spots with confidence interval of 99 (≥2 fold) with at
least 150-fluorescence intensity for both channel and 30𝜇m
spot size were considered good quality spots for analysis.
The microarray data were available from Gene Expres-
sion Omnibus (http://www.ncbi.nlm.nih.gov/geo; accession
number GSE55976).
2.7. Statistical Analysis. For microarray data management
and analysis, we used NCI/CIT microarray database (mAdb)
system. The one-way ANOVA was applied using mAdb
software for measurement of statistical significance in gene
expression among MPNs. For mAdb hierarchical clustering
we used uncentered correlation that applied a modified
Pearson correlation equation which assumes that the means
are 0.
3. Results
3.1. Analysis of Peripheral Blood Cells in MPN Patients
according to JAK2V617FMutant Allele Burden. We examined
the levels of peripheral blood cells from MPN patients in
correlation to JAK2V617Fmutant allele burden.We observed
63 patients with ET, 92 patients with PV, 50 patients with
PMF, 12 healthy subjects, and 10 patients with secondary ery-
throcytosis. Level of thrombocytes was reduced, while ery-
throcyte and hemoglobin levels were elevated in ET patients
heterozygous for JAK2V617F mutation versus ET patients
without JAK mutation (Table 1). PV patients heterozygous
and homozygous for JAK2V617F mutation had significantly
increased levels of CD34+ cells, leukocytes, thrombocytes,
and erythrocytes but reduced MCV compared to secondary
erythrocytosis. CD34+ cells were generally increased in
peripheral blood of PMF patients, particularly in JAK2V617F
mutation positive patients. The average number of CD34+
cells (cells/𝜇L) in peripheral blood was approximately 6 in
PV and ET and 111 in PMF group, increased in comparison
to mean value for healthy subjects (2.75 ± 1 cells/𝜇L). In
addition, leukocytes and erythrocytes were increased both
in heterozygous and homozygous JAK2V617Fmutated forms
comparing to PMF patients without mutation. We observed
lower thrombocyte levels and MCV in homozygous PMF
patients, while hemoglobin levels were significantly increased
in heterozygous PMF patients compared to JAK2V617F
unmutated PMF patients (Table 1).
3.2. Microarray Analysis of Total Gene Expression in CD34+
Cells of MPNs according to JAK2V617F Mutant Allele Burden.
Using microarray analysis, the total gene expression has
been examined separately in CD34+ cells of PV, ET, and
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0 6.3 (±3.4) 8.77 (±2.4) 1110 (±358) 4.6 (±0.4) 88.7 (±3.7) 134.1 (±14)
<50% 6.2 (±6.1) 9.1 (±3.5) 815 (±249)2 5 (±0.53)2 87 (±3.9) 142 (±13)1
PV
Sec Er 2.5 (±0.7) 7.25 (±1.9) 203 (±46) 5.34 (±0.4) 89.8 (±3.6) 161.6 (±13)
<50% 6.3 (±4.6)1 12.2 (±3.9)2 807 (±349)2 6.1 (±0.8)2 82 (±8.8)2 158.4 (±15)
>50% 9.4 (±8.2)1 17.3 (±9.5)2 631 (±270)2 6.5 (±0.9)2 74.6 (±8.8)2 152.4 (±17)
PMF
0 29.8 (±37) 8.8 (±3.1) 905 (±320) 4.4 (±0.44) 87.1 (±5.6) 126.5 (±17)
<50% 99 (±212) 12.9 (±5.1)2 804 (±364) 4.9 (±0.8)1 84 (±6.2) 138 (±14)1
>50% 126 (±158) 14.2 (±5.5)2 509 (±331)2 5.34 (±1.3)2 77.7 (±11)2 129.1 (±20)
𝑡-test: 1𝑝 < 0.05, 2𝑝 < 0.01 versus MPNs without JAK2 mutation (0) and secondary erythrocytosis (Sec Er).
PMF groups. A distribution of total gene expression of MPN
CD34+ cells has been presented in comparison to controls
and according to JAK2V617Fmutant allele burden (Figure 1).
The quantity of shared genes in CD34+ cells was presented
by Venn diagram in JAK2V617F heterozygous, homozygous,
and mutation-free forms (Figure 1). Moreover, the statistical
analyses of total gene expression have been performed in
PV, ET, and PMF according to JAK2V617F mutant allele
burden (see Supplemental Table 1 in Supplementary Material
available online at http://dx.doi.org/10.1155/2015/453020).We
observed 261 significantly changed genes (𝑝 < 0.01) in PV,
82 significant genes (𝑝 < 0.01) in ET, and 94 genes (𝑝 <
0.05) in PMF comparing to controls and sporadically among
MPNs (Supplemental Table 1). ET and PMF shared 43% and
26%of their significantly changed geneswith PV, respectively.
CHMP5 gene expression was generally increased in MPNs
and further on augmented by JAK2V617F allele burden.
SOD2 gene expression was also generally increased in MPNs
but only in PV augmented by JAK2V617F allele burden.
WAC gene expression was generally increased in PV, ET, and
heterozygous PMF patients. CCND3, HN1, and LOC124685
were only significantly upregulated genes simultaneously in
ET and PMF compared to control subjects (Supplemental
Table 1).
3.3. JAK-STAT Signaling Pathway Related Genes in CD34+
Cells of MPNs. The examination of JAK2V617F mutant
allele burden influence has been expanded toward JAK-
STAT signaling pathway in CD34+ cells of MPNs. According
to Table 2, several genes involved in JAK-STAT signaling
have been modified by JAK2V617F allele burden. Colony
stimulating factor 3 receptor (CSF3R) has been significantly
increased in JAK2V617F positive ET and PV patients. The v-
akt murine thymoma viral oncogene homolog 2 (AKT2) has
been significantly increased in JAK2V617F homozygous PV
and JAK2V617F positive PMF patients. Cyclin D3 (CCND3)
has been generally augmented in MPNs not influenced
by JAK2V617F mutation. Pim-1 oncogene (PIM1) has been
also generally augmented in MPNs but reached statistical
significance only in PV, similar to protein tyrosine phos-
phatase, nonreceptor type 11 (PTPN11). However, PTPN6 has
been significantly increased only in JAK2V617F heterozy-
gous ET patients. STAT1 and STAT2 gene expression have
been increased in heterozygous ET and PV patients, while
STAT3 only in homozygous PV patients. STAT5A has been
significantly decreased in ET and PMF with no JAK2V617F
mutation as well as in homozygous PV patients (Table 2). In
addition, these JAK-STAT signaling related genes were also
shown in hierarchical clustering analysis to illustrate their
associations (Figure 2).The genes only and steadily expressed
in homozygous PV were GRB2, IL15, LEPR, and PIK3CA
(Table 2).
3.4. IL-6 and Inflammatory Signaling Pathways Related Gene
Expression in CD34+ Cells ofMPNs. Regarding IL-6 signaling
pathway related genes several of themwere already presented
in Table 2, such as PTPN11, STAT3, JAK1, JAK2, interleukin 6
signal transducer (IL6ST), and growth factor receptor-bound
protein 2 (GRB2). IL6ST has been increased in CD34+ cells of
JAK2V617F mutation positive ET and PV patients (Table 2).
MAP2K1 was significantly increased in CD34+ cells of PV
(Table 3). RAF1 and FOS gene expression were increased in
ET and PV but do not reach statistical significance compared
to controls (Table 3). Other proinflammatory pathways such
as NF-𝜅B and TGF-𝛽 signaling demonstrated elevation of
TNFRSF1A and TRADD genes expression in CD34+ cells of
PMF and PV, respectively, as well as decrease of CDKN2B
and increase of TFDP1 genes in PMF (Table 3). Anti-
inflammatory IL-10 signaling pathway related genes BLVRA
and HMOX1 demonstrated increased expression in CD34+
cells of PV and ET, respectively (Table 3).
3.5. IL-6 Protein Levels in MPNs according to JAK2V617F
Mutant Allele Burden. We examined IL-6 protein levels
in peripheral blood (plasma) and bone marrow of MPNs
in accordance with JAK2V617F mutant allele burden. IL-6
protein levels were generally increased in plasma of MPNs
reaching statistical significance in majority of patients, not
influenced by JAK2V617F mutant allele burden (Figure 3(a)).
Furthermore, there is a positive correlation between IL-6
protein levels and erythrocytes (𝑟 = 0.933, 𝑝 < 0.01),
hemoglobin (𝑟 = 0.733,𝑝 < 0.05), and hematocrit (𝑟 = 0.818,
𝑝 < 0.05) levels in PV patients heterozygous for JAK2V617F
mutation. IL-6 protein levels were also commonly and
significantly increased in bone marrow stromal cells of












































Figure 1: Microarray study of gene expression in CD34+ cells from peripheral blood of MPN patients.The Venn diagram shows similarity of
total gene expression in controls (𝑛 = 8) and (a) JAK2V617F heterozygous and no mutation ET forms (𝑛 = 9), (b) JAK2V617F heterozygous
and homozygous PV forms (𝑛 = 7), and (c) JAK2V617F heterozygous and no mutation PMF forms (𝑛 = 4).
MPNs (Figure 3(b)). This bone marrow augmentation of IL-
6 expression was more prominent in JAK2V617F positive ET
and PMF patients (𝑝 < 0.01, Figure 3(b)).
4. Discussion
Presence of JAK2V617F mutation correlated with a reduced
level of thrombocytosis in ET and increased absolute number
of circulating CD34+ cells, leukocytosis, and erythrocyto-
sis in patients with PV. In addition, increased JAK2V617F
allele burden augmented leukocytosis and erythrocytosis but
reduced thrombocytosis and MCV in patients with PMF.
Using Venn diagram, a distribution of gene expression has
been presented, with a list of significantly modified genes in
CD34+ cells ofMPNs, compared to controls and according to
JAK2V617F mutant allele burden. 261 significantly changed
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Table 2: Statistically significant genes related to JAK-STAT pathway in CD34+ cells of MPNs according to JAK2V617F mutant allele burden.
Control ET PV PMF
JAK2 − − + Hetero Homo − +
Genes AV ± SD AV ± SD AV ± SD AV ± SD AV ± SD AV ± SD AV ± SD
AKT2 0.94 ± 0.18 1.11 ± 0.58 0.80 ± 0.40 0.66 ± 0.37 1.3 ± 0.1∗∗ 0.7 ± 0.30 1.1 ± 0.17∗
CSF3R 2.83 ± 0.20 2.99 ± 0.37 3.8 ± 0.6∗∗ 3.2 ± 0.6∗ 3.2 ± 0.2∗∗ 2.92 ± 1.01 3.20 ± 0.50
CBL 0.49 ± 0.45 −0.1 ± 0.3∗ 0.28 ± 0.65 0.29 ± 0.06 0.61 ± 0.14 0.16 ± 0.85 0.79 ± 0.13
CCND2 0.30 ± 0.55 0.01 ± 0.05 −0.38 ± 0.6 0.56 ± 0.39 0.38 ± 0.38 0.02 ± 0.20 0.33 ± 0.86
CCND3 0.21 ± 0.22 1.1 ± 0.5∗∗ 0.9 ± 0.4∗∗ 0.66 ± 0.57 0.9 ± 0.3∗∗ 1.2 ± 0.4∗∗ 0.76 ± 0.2∗
CNTFR 0.52 ± 0.99 0.65 ± 0.83 0.97 ± 0.71 0.25 ± 0.47 −1.03 ± 0.2 −1.2 −0.64 ± 1.3
CREBBP 0.23 ± 0.60 −0.35 ± 0.3 0.35 ± 0.34 0.45 ± 0.44 0.10 ± 0.51 −0.41 ± 0.6 0.05 ± 0.58
GRB2 1.65 2.05 1.91 ± 0.12 1.48
IFNAR2 0.51 ± 1.13 1.41 ± 0.46 1.76 ± 0.49 1.38 ± 0.25 1.32 ± 0.38 1.23 ± 0.69 0.83
IFNGR1 0.77 ± 0.22 0.92 1.14 ± 0.28 0.85 ± 0.12 1.18 ± 0.40 1.88
IFNGR2 0.77 ± 0.13 2.06 1.58 ± 0.60 1.94 ± 0.48 2.0 ± 0.1∗∗ 1.96 1.87
IL10RB 0.96 ± 0.28 0.88 ± 0.55 1.52 ± 0.60 1.23 ± 0.49 0.99 ± 0.79 0.86 ± 1.01 0.80 ± 0.05
IL11RA 1.69 ± 0.13 0.31 1.87 1.66 ± 0.15 1.92 ± 0.39 1.49
IL15 1.1 2.14 2.24 ± 0.04
IL15RA 0.76 ± 0.47 0.19 ± 0.09 0.50 ± 0.34 0.27 ± 0.19 0.41 ± 0.07 0.16 ± 0.32 0.60 ± 0.39
IL23A −1.18 ± 0.2 −0.7 ± 0.4∗ −1.11 ± 0.4 −0.75 ± 0.4 −0.5 ± 0.4∗ −1.3 ± 0.2∗ −1.7 ± 0.02∗∗
IL6ST −1.10 ± 0.2 −0.46 ± 0.4 0.1 ± 0.6∗∗ 0.06 ± 0.4∗ −0.1 ± 0.6∗ −0.92 ± 0.7 −0.84
JAK1 0.88 ± 0.24 1.2 0.93 1.42 ± 0.03 1.7 ± 0.1∗∗ 1.47 1.11
JAK2 2.25 3.54 ± 0.81 4.07 ± 0.27 3.96 ± 0.57 3.01
LEPR 0.18 0.92 0.77 0.81 0.39 ± 0.21 1.13 1.07
MYC −1.86 ± 0.3 −2.28 ± 0.2 −1.70 ± 0.4 −1.27 ± 0.7 −1.58 ± 0.5 −1.70 ± 1.1 −0.79
PIAS1 0.48 ± 0.38 0.04 ± 0.49 1.10 ± 0.61 1.04 ± 0.37 0.97 ± 0.12 0.21 ± 0.69 0.61 ± 0.05
PIAS4 1.88 ± 0.43 2.05 ± 0.20 2.24 ± 0.77 1.86 ± 0.42 1.84 ± 0.12 1.89 ± 0.12 2.06 ± 0.51
PIK3CA 1.45 1.51 1.64 ± 0.13
PIK3R1 0.72 1.04 2.41 2.45 ± 0.68 1.95 2.21
PIM1 0.28 ± 0.2 0.90 ± 0.19 1.10 ± 0.48 1.37 ± 0.4∗ 1.42 ± 0.4∗ 1.03 ± 0.38 0.82 ± 0.28
PTPN11 0.78 ± 0.53 1.10 ± 0.46 0.84 ± 0.38 1.09 ± 0.43 1.03 ± 0.4∗ 0.91 0.44 ± 0.16
PTPN6 0.44 ± 0.43 0.70 ± 0.18 1.35 ± 0.4∗ 1.12 ± 0.60 0.41 ± 0.19 0.05 ± 0.23 0.47
SOCS2 1.48 ± 0.61 1.12 ± 0.94 1.21 ± 0.87 1.71 ± 0.73 1.75 ± 1.09 2.06 ± 0.04 2.20 ± 0.90
SPRED2 0.17 ± 0.34 −0.45 ± 0.2 −0.58 −0.82 −0.73
SPRY4 −0.13 ± 0.7 −0.14 ± 0.7 −0.35 ± 0.2 −0.61 ± 0.2 −1.14 ± 0.2 −1.03 −1.00 ± 0.7
STAT1 3.60 ± 0.55 3.37 ± 0.80 4.68 ± 0.8∗ 4.4 ± 0.05∗ 5.1 ± 0.5∗∗ 3.31 ± 1.44 4.18 ± 0.39
STAT2 1.45 ± 0.51 1.57 ± 0.38 2.39 ± 0.6∗ 2.25 ± 0.2∗ 2.01 ± 0.42 1.58 ± 0.74 1.75 ± 0.35
STAT3 1.13 ± 0.26 1.54 ± 0.07 1.32 ± 0.30 1.05 ± 0.81 1.8 ± 0.3∗∗ 1.59 ± 0.13 1.62 ± 0.57
STAT5A 1.39 ± 0.25 0.8 ± 0.01∗ 0.90 ± 0.53 0.99 ± 0.43 1.01 ± 0.2∗ 0.5 ± 0.2∗∗ 1.93
TYK2 0.36 ± 0.28 0.63 0.85 ± 0.43 0.75 ± 0.33 0.35 ± 0.32 0.58
∗
𝑝 < 0.05, ∗∗𝑝 < 0.01, and gene expression in MPNs versus control.
genes in PV have been observed, 82 in ET, and 94 genes in
PMF. We demonstrated that majority of JAK-STAT signaling
pathway related genes have been augmented in MPNs with
increased JAK2V617F allele burden, except STAT5 gene.
Proinflammatory IL-6 (IL6ST, PTPN11), NF-𝜅B (TNFRSF1A,
TRADD), and TGF-𝛽 (TFDP1) signaling pathways demon-
strated increase of the related genes, as well as certain anti-
inflammatory IL-10 signaling pathway related genes (BLVRA,
HMOX1) in CD34+ cells of MPNs. IL-6 cytokine levels were
increased in plasma of MPNs, as well as IL-6 protein levels
in bone marrow stroma of MPNs, where they demonstrated
dependence of JAK2V617F presence in ET and PMF pa-
tients.
According to a large study with 1545 PV patients, median
hemoglobin level was 184 g/L (in range 151–265), median
leukocyte count was 10.4× 109/L (in range 3–171), andmedian
platelet count was 466 × 109/L (in range 7–2370). Leukocyto-
sis was present in 49%, while thrombocytosis in 53% of PV
patients [20]. In other study with 327 PV patients, median
hemoglobin level was 176 g/L, median leukocyte count was
13 × 109/L, and median platelet count was 515 × 109/L [21].
In study with 707 PMF patients, median hemoglobin level
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Figure 2: Hierarchical clustering of JAK-STAT signaling pathway related genes expressed in CD34+ cells of MPNs. The color indicates the
relative fold expression of each gene: red indicates increased expression, green negative expression, and black not changed expression, while
gray stands for absent expression per each examined sample. The gene correlations are uncentered.
was 110 g/L (in range 63–149), median leukocyte count was
13 × 109/L (in range 2.7–35.0), and median platelet count
was 515 × 109/L (in range 44–990) [22]. In next study with
612 MPN patients, mean hemoglobin level was 137, 174, and
119 g/L, mean leukocyte count was 10.2, 12.4, and 13.3 × 109/L,
and mean platelet count was 889, 579, and 517 × 109/L for
ET, PV, and PMF patients, respectively [23]. According to a
small study with 21 ET patients, median red cell level was 4.46
× 1012/L (3.14–5.78), median hemoglobin level was 135 g/L
(105–166), median leukocyte count was 10.7 × 109/L (5.1–
19.8), and median platelet count was 872 × 109/L (310–1443).
In the same report with 17 PV patients, median red cell
level was 6.15 × 1012/L (5.09–7.95), median hemoglobin level
was 165 g/L (138–205), median leukocyte count was 10.0 ×
109/L (6.6–27.2), and median platelet count was 501 × 109/L
(221–936) [24]. Reported laboratory findings are in range of
our presented results. In our study, hemoglobin mean level
158 g/L for PVwas reduced, 142 g/L for ETwas similar, 138 g/L
for PMF was increased in comparison to other studies but is
still in range of the observed results [20, 21, 24]. The levels
of red blood cells and leukocytes in our MPN patients were
similar to previous reports. The level of platelets in our ET
patients was similar but elevated in PV and PMF patients
in comparison to previous results. However, the increased
values were within the limit of the reported results.
Median numbers and ranges of circulating CD34+ cells
were 2.3 × 106/L (0–5) in control subjects, 2.2 × 106/L (0–14)
in those with PV, 2.4 × 106/L (0–14) in those with ET, and
114 × 106/L (6–2520) in PMF patients [25]. Comparing to our
study, CD34+ cell levels were reduced in ET and PV patients
but were still within range, while they were similar for PMF
patients (Table 1). More similar median levels of circulating
CD34+ cells in PV and ET have been observed in another
study: 8.9× 106/L (0–31) in thosewith PV, 4.1× 106/L (0–18) in
those with ET, and 60 × 106/L (11–449) in PMF patients [17].
A significant and positive correlation between the proportion
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(b) Bone marrow
Figure 3: IL-6 levels in peripheral blood and bone marrow of MPNs in accordance with JAK2V617F mutant allele burden. (a) IL-6 level
in peripheral blood of patients with MPN determined by ELISA (𝑛 = 7). (b) IL-6 level in bone marrow of patients with MPN determined
by immunohistochemistry. (−) no JAK2V617F, (+) heterozygosity, and (++) homozygosity for JAK2V617F mutation (𝑛 = 4-5, plus control
𝑛 = 6). Values are mean ± SEM. ∗𝑝 < 0.05, ∗∗𝑝 < 0.01 regarding MPNs versus Control.
of JAK2V716F mutant alleles and circulating CD34+ counts
in MPNs has been found. CD34+ cell counts were similar in
healthy subjects (median value 1.3 × 106/L) and individuals
with secondary erythrocytosis (median value 1.8 × 106/L).
However, PVpatients with JAK2V617F had higher circulating
CD34+ counts than healthy individuals without the mutation
[26]. This is in accordance with our observation. PV patients
carrying up to 50% JAK2 mutant alleles had slightly but
significantly higher CD34+ cell counts (median value 3.2 ×
106/L) than controls, doubled in our results. Moreover,
patients with PV and more than 50% JAK2V617F allele had
markedly higher CD34+ cell counts (median value 21.4 ×
106/L) than those with 50% or less mutant alleles [26]. This
value for CD34+ cell level in PV was doubled in comparison
to our result (9.4 × 106/L) for PV patients with more than
50% JAK2V617F allele. In addition, according to our results
ET patients regardless of JAK2mutant alleles had higher cir-
culating CD34+ counts than healthy individuals. Moreover,
PMF patients had also increased level of circulating CD34+
cells than healthy individuals, more elevated in patients with
JAK2V617F allele.
Chronic inflammation may be an initiator of clonal
evolution in patients with MPNs. The presence of elevated
leukocyte and thrombocyte counts inMPNsmay be the result
of both clonal myeloproliferation and chronic inflammation
presented by hypersensitivity to cytokine stimulation [27].
We demonstrated increased expression of JAK-STAT related
genes and increased IL-6 levels in MPNs. IL-6-JAK1-STAT3
signal transduction pathway had an important role in the
conversion of differentiated cancer cells into cancer stem
cells [28]. Inhibition of JAK blocked IL-6-induced phos-
phorylation of STAT3 but failed to block the phosphory-
lation of mitogen-activated protein kinase (MAPK) [29].
Another major signaling pathway for IL-6-type cytokines
was the MAPK cascade [2]. Soluble calreticulin induced
proinflammatory cytokine IL-6 in macrophages via MAPK-
NF-𝜅B signaling pathway [30]. SOCS1 expression was ele-
vated in MPN granulocytes but the level was independent
of JAK2V617F mutational status. SOCS3 is an inhibitor
of IL-6 and STAT3, regulated by DNA methylation. The
transcript levels of SOCS3 were increased in granulocytes
from JAK2V617F-positive MPN patients. Hypermethylation
of the SOCS3 promoter was identified in 32% of patients with
PMF but not in patients with ET and PV [31].
We presented expression of genes related to inflammatory
NF-𝜅B and TGF-𝛽 signaling in MPNs. IL-6 transsignaling
was dependent on STAT3 and mediated through enhanced
TGF-𝛽 signaling [4]. A dysregulation of NF-𝜅B was already
addressed as responsible for the MPNs [31]. NF-𝜅B dysreg-
ulation in microRNA-146a-deficient mice drove the devel-
opment of myeloid malignancies. MicroRNA-146a has been
implicated as a negative feedback regulator of NF-𝜅B acti-
vation. The mice also exhibited chronic myeloproliferation
in their bone marrow, with increased transcription of NF-
𝜅B-regulated genes [32]. NF-𝜅B was a central mediator of
TGF-𝛽 induction in monocytes from patients with PMF
[33]. A spontaneous activation of NF-𝜅B was also detected
in proliferating megakaryocytes and circulating CD34+ cells
of patients with PMF, involved in TGF-𝛽1 secretion [34].
Patients withMPNhad higher peripheral blood plasma levels
of both bioactive and total TGF-𝛽1 compared to healthy
controls [35]. TGFBR2 was significantly overexpressed in
advanced PMF stages produced by endothelial cells of the
increased microvessel network [36]. Expression of members
of bone morphogenetic protein (BMP) family, BMP1, BMP6,
BMP7, and BMP-receptor 2, was significantly increased in
advanced stages of PMF [36]. Cytokine IL-10 had increased
levels in plasma of PMF patients [8]. In our analysis, gene
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Table 4: Comparison of gene expression profiling between former and present studies in CD34+ cells of MPN subjects.
Studies Guglielmelli et al. [17] Jones et al. [18] Steidl et al. [19] Čokić et al.
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(12.625 probes) 1.185 genes
25.100 genes
(35.035 probes)
JAK2V617F Mixture of 8 mutatedand 7 nonmutated Not analyzed Not analyzed
Separated according to
mutant allele burden
Characterized genes 174 95 (48 upregulated and47 downregulated) 107
PV, 261, ET, 82,
PMF, 94
HC: healthy controls, PB: peripheral blood, and BM: bone marrow.
expression of receptor for IL-10 (IL10RB) was increased in
CD34+ cells of ET and PV and reduced in PMF with no
statistical significance.
The recent JAK1/2 inhibitor trials in MPNs unexpectedly
showed that reducing inflammation can be more beneficial
to patients than targeting gene mutants [37]. Increased level
of cytokine IL-6 was associated with shorter survival in
patients with PMF [8]. The proportion of hematopoietic
cells expressing the JAK2V617F mutation decreased after
in vitro differentiation of CD34+ cells in the presence of
optimal concentration of IL-6 and other growth factors
[38]. Panobinostat, a pan-deacetylase inhibitor that depletes
JAK2V617F levels and JAK/STAT signaling in MPN cells,
reduced IL-6 level in plasma of PMF patients [39]. More-
over, IL-6 secreted by stromal cells protected JAK2V617F
mutated cells, MPN clones, from JAK2 inhibitor therapy
[40]. Siltuximab, a chimeric anti-IL-6 monoclonal antibody,
did not reduce RBC transfusions in transfusion-dependent
patients with low- and intermediate-1-risk myelodysplastic
syndrome [41]. The addition of siltuximab to bortezomib did
not improve progression-free or overall survival regardless
of a numerical increase in response rate of patients with
relapsed or refractorymultiplemyeloma [42].The addition of
siltuximab to bortezomib-melphalan-prednisone improved
the complete response rate by 5%, overall response rate by
8%, and partial response rate by 20% in multiple myeloma
[43]. Siltuximab in combination with dexamethasone yielded
a partial response rate of 23% in patients with relapsed or
refractory multiple myeloma [44].
Formicroarray analyses of CD34+ cells we used amplified
RNA. Polacek et al. observed 94% overlap of the differentially
expressed genes when starting with 100 ng total RNA input in
the amplification procedure [45]. Greater than 90% overlap
has been reported with oligo arrays when starting with
250 ng total RNA input [46, 47]. In addition, the quality
of the array data was superior to that obtained using total
RNA [48]. Therefore, we used 300 ng total RNA input for
amplification and it is couple times higher than or similar to
the previous observations with more than 90% overlap. By
this approach, we greatly reduced the possibility of biases in
the relative representations of unique RNAs. Previous profile
reports included various quantities of examined genes from
purified CD34+ cells of PMF and PV subjects (Table 4) [17–
19]. We performed microarray studies with 25.100 genes in
CD34+ cells from the peripheral blood of MPN subjects.
According to different technical approaches, as presented in
Table 4 (we prepared amplifiedRNA fromperipheral blood of
individualMPNpatients and controls rather than performing
pools of RNA from patient groups and bone marrow derived
CD34+ cells), we found some minor overlap in differentially
expressed genes. In microarray study of well characterized
and significantly different genes performed by Guglielmelli
et al., FGFR1, KLF4, and TGFBI levels were decreased, while
IFITM1 level was increased in PMF CD34+ cells [17]. In
our study, FGFR4, KLF2 gene expression was increased in
PV, augmented by JAK2V617F mutant allele burden, while
TGFBI level was increased in PV and ET patients. IFITM1
level was also increased in our PV and ET CD34+ cells,
enhanced by JAK2V617Fmutant allele burden (Supplemental
Table 1). In microarray study of Jones et al., TNFRSF1A and
TGIF2-C20ORF24 were downregulated, while NCF2 gene
expression was upregulated in PMF CD34+ cells [18]. In
our study, NCF2 gene expression was upregulated in PV,
while TNFRSF1A was upregulated in JAK2V617F positive
ET patients. In gene expression profiling study by Steidl et
al., CAPNS1, CASP1, GPX1, and HSPA8 were downregulated,
while FGFR4, TGFBI, and IL-6 were upregulated in PV
CD34+ cells [19]. In our study, CAPNS1 and HSPA8 were
downregulated in PMF and PV, whereas CASP1, IL6ST, and
GPX1 were upregulated in PV and ET, respectively; FGFR4
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was upregulated in PV patients, augmented by JAK2V617F
allele burden.Therefore, the increased levels of inflammation
biomarkers (TGFBI, IL-6) were also detected in previous
microarray studies.
5. Conclusion
Besides determination of significantly changed genes in
CD34+ cells of MPNs, we confirmed activation of JAK-STAT
signaling related genes, such as CSF3R, IL6ST, PIM1, and
STAT1/2. Regarding parameters of inflammation, leukocyto-
sis was increased in PV and PMF, while thrombocytosis was
reduced in ET and PMF with JAK2V617F mutation. Proin-
flammatory cytokine IL-6 levels were generally increased in
peripheral blood and bone marrow of patients with MPN
but were more prominent in JAK2V617F mutation positive
ET and PMF patients. Therefore, JAK2V617F mutant allele
burden participated in inflammation biomarkers induction.
The presented inflammation biomarkers will provide a better
understanding of molecular mechanisms implicated in the
development and progression of MPNs.
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analyzed the data; Vladan P. Čokić wrote the paper; and Pavle
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